Browse

What is the most cost-effective strategy to screen for second primary colorectal cancers in male cancer survivors in Korea?

DC Field Value Language
dc.contributor.authorPark, Sang Min-
dc.contributor.authorKim, Sun-Young-
dc.contributor.authorEarle, Craig C.-
dc.contributor.authorJeong, Seung-Yong-
dc.contributor.authorYun, Young Ho-
dc.date.accessioned2012-05-23T01:26:01Z-
dc.date.available2012-05-23T01:26:01Z-
dc.date.issued2009-07-07-
dc.identifier.citationWORLD JOURNAL OF GASTROENTEROLOGY; Vol.15 25; 3153-3160ko_KR
dc.identifier.issn1007-9327-
dc.identifier.urihttps://hdl.handle.net/10371/76294-
dc.description.abstractAIM: To identify a cost-effective strategy of second primary colorectal cancer (CRC) screening for cancer survivors in Korea using a decision-analytic model. METHODS: A Markov model estimated the clinical and economic consequences of a simulated 50-year-old male cancer survivors` cohort, and we compared the results of eight screening strategies: no screening, fecal occult blood test (FOBT) annually, FOBT every 2 years, sigmoidoscopy every 5 years, double contrast barium enema every 5 years, and colonoscopy every 10 years (COL10), every 5 years (COL5), and every 3 years (COL3). We included only direct medical costs, and our main outcome measures were discounted lifetime costs, life expectancy, and incremental cost-effectiveness ratio (ICER). RESULTS: In the base-case analysis, the non-dominated strategies in cancer survivors were COL5, and COL3. The ICER for COL3 in cancer survivors was $5593/life-year saved (LYS), and did not exceed $10000/LYS in one-way sensitivity analyses. If the risk of CRC in cancer survivors is at least two times higher than that in the general population, COL5 had an ICER of less than $10500/LYS among both good and poor prognosis of index cancer. If the age of cancer survivors starting CRC screening was decreased to 40 years, the ICER of COL5 was less than $7400/LYS regardless of screening compliance. CONCLUSION: Our study suggests that more strict and frequent recommendations for colonoscopy such as COL5 and COL3 could be considered as economically reasonable second primary CRC screening strategies for Korean male cancer survivors. (C) 2009 The WIG Press and Baishideng. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherW J G PRESSko_KR
dc.subjectCost-effectivenessko_KR
dc.subjectSecond primary colorectal cancerko_KR
dc.subjectCancer survivorko_KR
dc.subjectScreeningko_KR
dc.titleWhat is the most cost-effective strategy to screen for second primary colorectal cancers in male cancer survivors in Korea?ko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor박상민-
dc.contributor.AlternativeAuthor김선영-
dc.contributor.AlternativeAuthor정승용-
dc.contributor.AlternativeAuthor윤영호-
dc.identifier.doi10.3748/wjg.15.3153-
dc.citation.journaltitleWORLD JOURNAL OF GASTROENTEROLOGY-
dc.description.citedreferencePark SM, 2007, J CLIN ONCOL, V25, P4835, DOI 10.1200/JCO.2006.10.3416-
dc.description.citedreferenceJung KW, 2007, J KOREAN MED SCI, V22, pS5-
dc.description.citedreference*WORLD BANKS GLOB, 2007, WORLD DEV IND 2007-
dc.description.citedreferenceSmith RA, 2006, CA-CANCER J CLIN, V56, P11-
dc.description.citedreferenceChoe JW, 2007, J GASTROEN HEPATOL, V22, P1003, DOI 10.1111/j.1440-1746.2007.04774.x-
dc.description.citedreferenceSMITH RA, 2006, CA CANC J CLIN, V56, P49-
dc.description.citedreference*MIN HLTH WELF KOR, 2006, NAT CANC SCREEN PROG-
dc.description.citedreferenceLadabaum U, 2005, GASTROENTEROLOGY, V129, P1151, DOI 10.1053/j.gastro.2005.07.059-
dc.description.citedreferenceDikshit RP, 2005, CANCER, V103, P2326, DOI 10.1002/cncr.21051-
dc.description.citedreferenceSHIN HR, 2005, CANC RES TREAT, V37, P325-
dc.description.citedreferencePARK SM, 2005, KOREA WORLD J GASTRO, V11, P1587-
dc.description.citedreferenceEichler HG, 2004, VALUE HEALTH, V7, P518-
dc.description.citedreferenceCotton PB, 2004, JAMA-J AM MED ASSOC, V291, P1713-
dc.description.citedreferenceMisra T, 2004, CAN J GASTROENTEROL, V18, P221-
dc.description.citedreference*NAT HLTH INS CORP, 2004, CONTR MED PRIC NAT H-
dc.description.citedreference*NAT CANC I, 2004, SURV EP RES SEER-
dc.description.citedreference*US DEP HHS, 2004, LIV CANC FIND NEW BA-
dc.description.citedreference*NAT HLTH INS CORP, 2002, 2001 RES CLIN PRACT-
dc.description.citedreference*US PREV SERV TASK, 2002, COL CANC SCREEN SUMM-
dc.description.citedreferenceBAE JM, 2002, CANC RES TREAT, V34, P319-
dc.description.citedreferenceLieberman DA, 2001, NEW ENGL J MED, V345, P555-
dc.description.citedreferenceDong C, 2001, INT J CANCER, V93, P155-
dc.description.citedreferenceKavic SM, 2001, AM J SURG, V181, P319-
dc.description.citedreference*NAT STAT OFF REP, 2001, ANN REP CAUS DEATH S-
dc.description.citedreferenceHUNINK M, 2001, DECISION MAKING HLTH, P277-
dc.description.citedreferenceAnderson ML, 2000, AM J GASTROENTEROL, V95, P3418-
dc.description.citedreferenceKim DH, 2000, J KOREAN MED SCI, V15, P675-
dc.description.citedreferenceFrazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954-
dc.description.citedreferenceWinawer SJ, 2000, NEW ENGL J MED, V342, P1766-
dc.description.citedreferenceKhandker RK, 2000, INT J TECHNOL ASSESS, V16, P799-
dc.description.citedreferenceDesch CE, 1999, J CLIN ONCOL, V17, P1312-
dc.description.citedreferenceWinawer SJ, 1999, GASTROINTEST ENDOSC, V49, pS63-
dc.description.citedreferenceKIM TS, 1999, KOREAN J GASTROINTES, V19, P887-
dc.description.citedreferenceGlick S, 1998, AM J ROENTGENOL, V170, P629-
dc.description.citedreferenceRex DK, 1997, GASTROENTEROLOGY, V112, P24-
dc.description.citedreferenceSHIMBO T, 1994, INT J TECHNOL ASSESS, V10, P359-
dc.description.citedreferenceAHLQUIST DA, 1992, CANCER, V70, P1259-
dc.description.citedreferenceWAGNER JL, 1991, ANN INTERN MED, V115, P807-
dc.description.citedreferenceHIXSON LJ, 1991, GASTROINTEST ENDOSC, V37, P125-
dc.description.citedreferenceKIM KH, 1991, J KOREAN SURG SOC, V41, P215-
dc.description.citedreferenceEDDY DM, 1990, ANN INTERN MED, V113, P373-
dc.description.citedreferenceSTRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009-
dc.description.citedreferenceEIDE TJ, 1978, CANCER, V42, P2839-
dc.description.citedreferenceMUTO T, 1975, CANCER, V36, P2251-
dc.description.citedreferenceSPRATT JS, 1962, JAMA-J AM MED ASSOC, V179, P337-
dc.description.citedreferenceJACKMAN RJ, 1951, SURG GYNECOL OBSTET, V93, P327-
dc.description.tc2-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Family Medicine (가정의학전공)Journal Papers (저널논문_가정의학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse